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INDOLE COMPOUNDS AND THEIR USE AS 
RADIATION SENSITIZING AGENTS AND 
CHEMOTHERAPEUTIC AGENTS 
PRIOR APPLICATIONS 
This invention claims bene?t to US. Patent Application 
No. 61/194,754, ?led Sep. 30, 2008, the contents ofWhich is 
incorporated herein in its entirety. 
FIELD OF THE INVENTION 
Generally, the present invention relates to the ?eld of radia 
tion sensitiZers. Additionally, the present invention relates to 
the ?eld of chemotherapeutic agents. 
One aspect of the present invention relates to novel indole 
compounds. Another aspect of the present invention relates to 
the use of indole compounds as radiation sensitiZers. 
Another aspect of the present invention relates to the use of 
indole compounds as chemotherapeutic agents. 
Another aspect of the present invention is 5-((N-benZyl 
1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-tri 
ones & (Z)-5-((N-benZyl-1H-indol-3-yl)methylene)imida 
Zolidine-2,4-diones and analogs thereof. Another aspect of 
the present invention is the use of 5-((N-benZyl-1H-indol-3 
yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones & (Z)-5 
((N-benZyl-1H-indol-3 -yl)methylene)imidaZolidine-2,4-di 
ones and analogs thereof as radiation sensitiZers. 
Another aspect of the present invention is 4-((3-((2,4,6 
Tri oxotetrahydropyrimidin- 5 (6H)-ylidene)methyl) - 1 H-in 
dol-1-yl)methyl)benZo-nitrile, and Methyl-4-((3-((2,4,6-tri 
oxotetrahydro pyrimidin-5(6H)-ylidene)methyl)- 1 H-indol 
1-yl)methyl)benZoate, and uses thereof, including the uses 
described herein. 
These and other aspects and uses Would be evident to one 
of ordinary skill in the art. 
BACKGROUND OF THE INVENTION 
Radiotherapy is the treatment of cancer and other diseases 
With ioniZing radiation. Radiotherapy is used in curative 
therapy, palliative therapy, adjuvant therapy after or before 
surgery, simultaneous radio-chemotherapy, etc. Radio 
therapy is successful because ioniZing radiation kills dividing 
cells and is thus slightly more toxic to fast groWing cancer 
cells. Radiotherapy may be used to treat localiZed solid 
tumors, such as cancers of the skin, tongue, larynx, brain, 
breast, or uterine cervix. Agents Which are used to potentiate 
the effectiveness of radiation therapy in destroying unWanted 
cells are radiation sensitiZing agents. Various attempts have 
been made to develop a radiation sensitiZer that reduces the 
radiation dose and adverse drug reactions Without compro 
mising the therapeutic effect of radiotherapy. 
For example, 7-Hydroxystaurosporine (UCN-Ol) is used 
as a radiosensitiZing agent (Zhouguang et al., 2003) in radio 
therapy to increase the radiosensitivity of tumor cells. The 
sulfonamide-substituted indolinones have been invented as 
radiation sensitiZing agents (Anthony et al., US. Pat. Appl. 
Publ. 2004, 46 pp), Which are capable of enhancing radio 
therapy by inhibiting DNA-protein kinase (DNA-PK). 
Radiotherapy is often performed for various types of can 
cers such as gastric cancer, colorectal cancer, pancreatic can 
cer, head and neck cancer, esophageal cancer, lung cancer, 
and breast cancer that are advanced to stage III or IV. 
Radiation therapy combined With adjuvant hyperthermia 
has the potential to provide outstanding local-regional control 












radiation sensitiZer, yielding thermal enhancement factors of 
up to 5.0 (Kampinga and Dikomey, 2001; Raaphorst and 
AZZam, 1983). HoWever, hyperthermia is limited clinically as 
a result of the technical problems of heat delivery (Nielsen et 
al., 2001). Hence there is an urgent need to develop pharma 
cological agents that can be used to replace hyperthermia. 
Previous Work has established that indomethacin can act as a 
radiation sensitiZer (Bradbury et al., 2001 ; Locke et al., 2002) 
and enhancer of thermal radiosensitiZation, and also it has 
been shoWn from other independent Work that indomethacin 
loWers the temperature necessary for the heat-induced protein 
aggregation and loWers the temperature necessary for Hsf-l 
activation, such that a complete heat shock response can be 
attained at temperatures that are by themselves, insuf?cient 
for activation. Although indomethacin is used as a radiation 
sensitiZer in radiotherapy, it is highly toxic at high concen 
trations. Hence there is a need to invent pharmacological 
agents With loWer toxicity. 
The present inventors previously discovered novel indole 
as potent thermal radiosensitiZers capable of loWering the 
threshold for Hsfl activation and thermal sensitivity. Addi 
tionally, the present inventors previously discovered (Z)-2 
(N -benZyl indol -3 -ylmethylidene) quinuclidin-3 -ol and 
Z-(z)-2-[N-(4-chlorobenZyl)indole-3-ylmethylidene]quinu 
clidin-3-ol as potent thermal radiosensitiZers capable of loW 
ering the threshold for Hsfl activation and thermal sensitivity 
(Sekhar et al. 2007; Sonar et al. 2007). These compounds 
needed 410 C. temperature to produce radiosensitiZation. It is 
dif?cult to achieve such temperatures in tumors. In order to 
loWer the temperatures, the above compounds Were modi?ed 
and tested for their ability to induce heat shock effect and 
?nally radiosensitiZation. 
The indole derived Aplysinopsin analogs have been 
reported as potent and selective cytotoxic agents against can 
cer cells. These observations prompted us to design and syn 
thesiZe a series of novel indole derivatives, including substi 
tuted 5 ((N-BenZyl- 1 H-indol-3 -yl)methylene)pyrimidine-2, 
4,6(1H,3H,5H)-triones & (Z)-5((N-benZyl-1H-indol-3-yl) 
methylene)imidaZolidine-2,4-diones and their related 
compounds With various substitutions onboth the indolic ring 
and the N-benZyl group that are radiation sensitiZers by elimi 
nating the necessity of heat. 
SUMMARY AND ASPECTS OF THE PRESENT 
INVENTION 
The present invention comprises novel structural entities 
have been designed and synthesiZed that constitute a series of 
novel functionaliZed indole analogs and other molecules 
structurally related to indomethacin in order to maximiZe 
radiosensitiZation activity and minimize toxicity. 
Another object of the present invention is to provide a 
radiotherapy enhancer that can reduce the radiation dose and 
adverse drug reactions When used in combination With cancer 
radiotherapy. 
One embodiment of the present invention is a series of 
novel substituted N-benZyl aplysinopsin analogs Were syn 
thesiZed by aldol condensation of the appropriate substituted 
N-benZyl indole-3-carboxaldehyde With a selection of active 
methylene compounds like barbituric acid & its related com 
pounds, hydantoin & its related compounds. The structure 
and purity of these derivatives Was veri?ed by 1H and 13 C 
NMR spectroscopy. 
As a result, novel substituted 5((N-BenZyl-1H-indol-3 -yl) 
methylene)pyrimidine-2,4,6(1H,3H,5H)-triones & (Z)-5 
((N-benZyl-1H-indol-3 -yl)methylene)imidaZo -lidine-2,4-di 
ones and their related compounds Were synthesized and 
US 8,304,421 B2 
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evaluated for their radiosensitiZation properties against 
HT-29 cells. Also, embodiments Were tested against tubule 
formation by HUVECs to assess their potency to inhibit 
angiogenesis. As an example, Compound 1 inhibited the 
tubule formation by HUVECs, shoWn beloW. 
An additional aspect of the present invention is a cancer 
treatment method provided by using a composition of the 
present invention and radiation in combination. Tumors for 
Which this treatment method can be used are not particularly 
limited. This method is particularly suitable for cancers With 
high radiation sensitivity. HoWever, since the radiation 
enhancer of the present invention can also increase radiation 
sensitivity of cancers that are considered to have loW sensi 
tivity, improvement of the effect of cancer radiotherapy can 
be expected. Examples of such cancers include head and neck 
cancer, esophageal cancer, gastric cancer, colorectal cancer, 
liver cancer, gallbladder/bile duct cancer, pancreatic cancer, 
lung cancer, breast cancer, bladder cancer, prostate cancer, 
cervical cancer, brain tumor, malignant lymphoma, acute leu 
kemia, chronic leukemia, medulloblastoma, retina retino 
blastoma, neuroblastoma, Wilms’ tumor, Hodgkin’s disease, 
multiple myeloma, plasmacytoma, thymoma, basal cell can 
cer, squamous cancer, EWing’s tumor, thyroid cancer, ovary 
cancer, salivary gland cancer, teratoma, malignant mela 
noma, neuroglioma, renal cell carcinoma, osteosarcoma, and 
so forth. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The ?gures are presented as being exemplary of the present 
invention, and are not to be construed as being limiting 
thereof. In general, the ?gures shoW experimental data that 
provide evidence of the radiation sensitiZation properties of 
the indole analogs described herein. 
FIG. 1 is a chart that shoWs the results of test in connection 
With Compound 1. More speci?cally, Compound 1 Was tested 
on HT-29 cells for colony formation assay. Various concen 
trations of Compound 1 Was used to assess the potency of the 
compound in exerting radiation sensitiZation property. HT-29 
cells Were treated With Compound 1 for 30 min and various 
doses of radiation Was applied. The cells Were incubated for 
90 min more. The cells Were Washed With PBS and fresh 
medium Was added. Colonies that Were formed after 2 Weeks 
of incubation, Were counted and corrected for drug toxicity 
and expressed as survival fraction. 
FIG. 2: HT-29 cells Were treated With Compound 1 for 2 
hrs. The drug Was Washed off With PBS and fresh medium Was 
added. The cells Were incubated for 5 more hours and nuclear 
protein Was extracted and Gel Mobility Shift Assay Was per 
formed as described in Experimental section, beloW. 
FIG. 3: Nuclear extracts obtained above Were used to detect 
the expression of HSP70 protein by Western Blot. Actin Was 
used as loading control. 
FIG. 4 shoWs the e?iciency of various drugs that Were 
synthesiZed (compounds 1, 2, 7, 8, 9, and 10) in the present 
investigation Were analyZed for radiation sensitiZation. 
FIG. 5: HUVECs Were plated on Matrigel, then treated 
Wither DMSO or Compound 1 for 24 hrs. Tubule formation 
Was assessed by looking under microscope. Compound 1 
inhibited tubule formation. 
FIG. 6 shoWs YTR increases radiation-induced phospho 
rylation of H2AX, a biochemical measure of DNA double 
strand breaks 
FIG. 7 shoWs inhibition of tumor groWth in connection 












DETAILED DESCRIPTION OF THE INVENTION 
The present invention can be understood more readily by 
reference to the folloWing detailed description of the inven 
tion and the Examples included therein. 
Before the present compounds, compositions, and/or 
methods are disclosed and described, it is to be understood 
that they are not limited to speci?c synthetic methods unless 
otherWise speci?ed, or to particular reagents unless otherWise 
speci?ed, as such may, of course, vary. It is also to be under 
stood that the terminology used herein is for the purpose of 
describing particular aspects only and is not intended to be 
limiting. Although any methods and materials similar or 
equivalent to those described herein can be used in the prac 
tice or testing of the present invention, example methods and 
materials are noW described. 
All publications mentioned herein are incorporated herein 
by reference to disclose and describe the methods and/or 
materials in connection With Which the publications are cited. 
The publications discussed herein are provided solely for 
their disclosure prior to the ?ling date of the present applica 
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica 
tion by virtue of prior invention. Further, the dates of publi 
cation provided herein can be different from the actual pub 
lication dates, Which need to be independently con?rmed. 
As used in the speci?cation and the appended claims, the 
singular forms “a,” “an” and “the” include plural referents 
unless the context clearly dictates otherWise. Thus, for 
example, reference to “a functional group,” “an alkyl,” or “a 
residue” includes mixtures of tWo or more such functional 
groups, alkyls, or residues, and the like. 
Ranges can be expressed herein as from “about” one par 
ticular value, and/or to “about” another particular value. 
When such a range is expressed, a further aspect includes 
from the one particular value and/or to the other particular 
value. Similarly, When values are expressed as approxima 
tions, by use of the antecedent “about,” it Will be understood 
that the particular value forms a further aspect. It Will be 
further understood that the endpoints of each of the ranges are 
signi?cant both in relation to the other endpoint, and inde 
pendently of the other endpoint. It is also understood that 
there are a number of values disclosed herein, and that each 
value is also herein disclosed as “about” that particular value 
in addition to the value itself. For example, if the value “10” 
is disclosed, then “about 10” is also disclosed. It is also 
understood that each unit betWeen tWo particular units are 
also disclosed. For example, if 10 and 15 are disclosed, then 
ll, l2, l3, and 14 are also disclosed. 
As used herein, the terms “optional” or “optionally” means 
that the subsequently described event or circumstance can or 
can not occur, and that the description includes instances 
Where said event or circumstance occurs and instances Where 
it does not. 
As used herein, the term “subject” refers to a target of 
administration. The subject of the herein disclosed methods 
can be a vertebrate, such as a mammal, a ?sh, a bird, a reptile, 
or an amphibian. Thus, the subject of the herein disclosed 
methods can be a human, non-human primate, horse, pig, 
rabbit, dog, sheep, goat, coW, cat, guinea pig or rodent. The 
term does not denote a particular age or sex. Thus, adult and 
neWbom subjects, as Well as fetuses, Whether male or female, 
are intended to be covered. A patient refers to a subject 
afflicted with a disease or disorder. The term “patient” 
includes human and veterinary subjects. 
US 8,304,421 B2 
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As used herein, the term “treatment” refers to the medical 
management of a patient With the intent to cure, ameliorate, 
stabilize, or prevent a disease, pathological condition, or dis 
order. This term includes active treatment, that is, treatment 
directed speci?cally toWard the improvement of a disease, 
pathological condition, or disorder, and also includes causal 
treatment, that is, treatment directed toWard removal of the 
cause of the associated disease, pathological condition, or 
disorder. In addition, this term includes palliative treatment, 
that is, treatment designed for the relief of symptoms rather 
than the curing of the disease, pathological condition, or 
disorder; preventative treatment, that is, treatment directed to 
minimizing or partially or completely inhibiting the develop 
ment of the associated disease, pathological condition, or 
disorder; and supportive treatment, that is, treatment 
employed to supplement another speci?c therapy directed 
toWard the improvement of the associated disease, pathologi 
cal condition, or disorder. 
As used herein, the term “prevent” or “preventing” refers to 
precluding, averting, obviating, forestalling, stopping, or hin 
dering something from happening, especially by advance 
action. It is understood that Where reduce, inhibit or prevent 
are used herein, unless speci?cally indicated otherWise, the 
use of the other tWo Words is also expressly disclosed. 
As used herein, the term “radiation sensitizer” can be con 
strued as an agent that enhances the anti-tumor effect more 
than irradiation alone by using the sensitizer in combination 
With irradiation. 
As used herein, the terms “administering” and “adminis 
tration” refer to any method of providing a pharmaceutical 
preparation to a subject. Such methods are Well knoWn to 
those skilled in the art and include, but are not limited to, oral 
administration, transderrnal administration, administration 
by inhalation, nasal administration, topical administration, 
intravaginal administration, ophthalmic administration, 
intraaural administration, intracerebral administration, rectal 
administration, and parenteral administration, including 
injectable such as intravenous administration, intra-ar‘terial 
administration, intramuscular administration, and subcutane 
ous administration. Administration can be continuous or 
intermittent. In various aspects, a preparation can be admin 
istered therapeutically; that is, administered to treat an exist 
ing disease or condition. In further various aspects, a prepa 
ration can be administered prophylactically; that is, 
administered for prevention of a disease or condition. 
As used herein, the term “effective amount” refers to an 
amount that is su?icient to achieve the desired result or to 
have an effect on an undesired condition. For example, a 
“therapeutically effective amount” refers to an amount that is 
suf?cient to achieve the desired therapeutic result or to have 
an effect on undesired symptoms, but is generally insuf?cient 
to cause adverse side affects. The speci?c therapeutically 
effective dose level for any particular patient Will depend 
upon a variety of factors including the disorder being treated 
and the severity of the disorder; the speci?c composition 
employed; the age, body Weight, general health, sex and diet 
of the patient; the time of administration; the route of admin 
istration; the rate of excretion of the speci?c compound 
employed; the duration of the treatment; drugs used in com 
bination or coincidental With the speci?c compound 
employed and like factors Well knoWn in the medical arts. For 
example, it is Well Within the skill of the art to start doses of a 
compound at levels loWer than those required to achieve the 
desired therapeutic effect and to gradually increase the dos 












daily dose can be divided into multiple doses for purposes of 
administration. Consequently, single dose compositions can 
contain such amounts or submultiples thereof to make up the 
daily dose. The dosage can be adjusted by the individual 
physician in the event of any contraindications. Dosage can 
vary, and can be administered in one or more dose adminis 
trations daily, for one or several days. Guidance can be found 
in the literature for appropriate dosages for given classes of 
pharmaceutical products. In further various aspects, a prepa 
ration can be administered in a “prophylactically effective 
amount”; that is, an amount effective for prevention of a 
disease or condition. 
Additionally, When used in reference to compounds of the 
invention, “an effective amount” refers to doses of compound 
suf?cient to provide circulating concentrations high enough 
to impart a bene?cial effect on the recipient thereof for at least 
either treating tumors or cancers, or enhancing radiation 
therapy. The precise amount to be administered can be deter 
mined by the skilled practitioner in vieW of desired dosages, 
side effects and medical history of the patient. 
As used herein, the term “pharmaceutically acceptable car 
rier” refers to sterile aqueous or nonaqueous solutions, dis 
persions, suspensions or emulsions, as Well as sterile poWders 
for reconstitution into sterile injectable solutions or disper 
sions just prior to use. Examples of suitable aqueous and 
nonaqueous carriers, diluents, solvents or vehicles include 
Water, ethanol, polyols (such as glycerol, propylene glycol, 
polyethylene glycol and the like), carboxymethylcellulose 
and suitable mixtures thereof, vegetable oils (such as olive 
oil) and inj ectable organic esters such as ethyl oleate. Proper 
?uidity can be maintained, for example, by the use of coating 
materials such as lecithin, by the maintenance of the required 
particle size in the case of dispersions and by the use of 
surfactants. These compositions can also contain adjuvants 
such as preservatives, Wetting agents, emulsifying agents and 
dispersing agents. Prevention of the action of microorgan 
isms can be ensured by the inclusion of various antibacterial 
and antifungal agents such as paraben, chlorobutanol, phenol, 
sorbic acid and the like. It can also be desirable to include 
isotonic agents such as sugars, sodium chloride and the like. 
Prolonged absorption of the injectable pharmaceutical form 
can be brought about by the inclusion of agents, such as 
aluminum mono stearate and gelatin, Which delay absorption. 
lnj ectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as poly 
lactide-polyglycolide, poly(orthoesters) and poly(anhy 
drides). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro 
emulsions Which are compatible With body tissues. The 
injectable formulations can be sterilized, for example, by 
?ltration through a bacterial-retaining ?lter or by incorporat 
ing sterilizing agents in the form of sterile solid compositions 
Which can be dissolved or dispersed in sterile Water or other 
sterile inj ectable media just prior to use. Suitable inert carriers 
can include sugars such as lactose. Desirably, at least 95% by 
Weight of the particles of the active ingredient have an effec 
tive particle size in the range of 0.01 to 10 micrometers. 
Additionally, Examples of pharmaceutically acceptable 
salts include alkaline or alkaline earth metal ion salts, par 
ticularly Na+ or K+ salts, or similar pharmaceutically-accept 
able inorganic salts. The above salt forms in all polymorphic 
and amorphous forms, may be in some cases hydrates or 
solvates With alcohols and other solvents. 
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As used herein, the term “substituted” is contemplated to 
include all permissible substituents of organic compounds. In 
a broad aspect, the permissible substituents include acyclic 
and cyclic, branched and unbranched, carbocyclic and het 
erocyclic, and aromatic and nonaromatic substituents of 
organic compounds. Illustrative substituents include, for 
example, those described beloW. The permissible substituents 
can be one or more and the same or different for appropriate 
organic compounds. For purposes of this disclosure, the het 
eroatoms, such as nitrogen, can have hydrogen substituents 
and/or any permissible substituents of organic compounds 
described herein Which satisfy the valences of the heteroat 
oms. This disclosure is not intended to be limited in any 
manner by the permissible substituents of organic com 
pounds. Also, the terms “substitution” or “substituted Wit ” 
include the implicit proviso that such substitution is in accor 
dance With permitted valence of the substituted atom and the 
substituent, and that the substitution results in a stable com 
pound, e.g., a compound that does not spontaneously undergo 
transformation such as by rearrangement, cycliZation, elimi 
nation, etc. 
The term “alkyl” as used herein is a branched or 
unbranched saturated hydrocarbon group of l to 24 carbon 
atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 
isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neo 
pentyl, hexyl, heptyl, octyl, nonyl, decyl, dode cyl, tetradecyl, 
hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group 
can be cyclic or acyclic. The alkyl group can be branched or 
unbranched. The alkyl group can also be substituted or unsub 
stituted. For example, the alkyl group can be substituted With 
one or more groups including, but not limited to, optionally 
substituted alkyl, cycloalkyl, alkoxy, amino, ether, halide, 
hydroxy, nitro, silyl, sulfo-oxo, or thiol, as described herein. 
A “loWer alkyl” group is an alkyl group containing from one 
to six (e.g., from one to four) carbon atoms. 
Throughout the speci?cation “alkyl” is generally used to 
refer to both unsubstituted alkyl groups and substituted alkyl 
groups; hoWever, substituted alkyl groups are also speci? 
cally referred to herein by identifying the speci?c 
substituent(s) on the alkyl group. For example, the term 
“halogenated alkyl” speci?cally refers to an alkyl group that 
is substituted With one or more halide, e. g., ?uorine, chlorine, 
bromine, or iodine. The term “alkoxyalkyl” speci?cally refers 
to an alkyl group that is substituted With one or more alkoxy 
groups, as described beloW. The term “alkylamino” speci? 
cally refers to an alkyl group that is substituted With one or 
more amino groups, as described beloW, and the like. When 
“alkyl” is used in one instance and a speci?c term such as 
“alkylalcohol” is used in another, it is not meant to imply that 
the term “alkyl” does not also refer to speci?c terms such as 
“alkylalcohol” and the like. 
This practice is also used for other groups described herein. 
That is, While a term such as “cycloalkyl” refers to both 
unsubstituted and substituted cycloalkyl moieties, the substi 
tuted moieties can, in addition, be speci?cally identi?ed 
herein; for example, a particular substituted cycloalkyl can be 
referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substi 
tuted alkoxy can be speci?cally referred to as, e.g., a “halo 
genated alkoxy,” a particular substituted alkenyl can be, e.g., 
an “alkenylalcohol,” and the like. Again, the practice of using 
a general term, such as “cycloalkyl,” and a speci?c term, such 
as “alkylcycloalkyl,” is not meant to imply that the general 
term does not also include the speci?c term. 
The term “cycloalkyl” as used herein is a non-aromatic 












Examples of cycloalkyl groups include, but are not limited to, 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, 
and the like. The term “heterocycloalkyl” is a type of 
cycloalkyl group as de?ned above, and is included Within the 
meaning of the term “cycloalkyl,” Where at least one of the 
carbon atoms of the ring is replaced With a heteroatom such 
as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. 
The cycloalkyl group and heterocycloalkyl group can be sub 
stituted or unsubstituted. The cycloalkyl group and heterocy 
cloalkyl group can be substituted With one or more groups 
including, but not limited to, optionally substituted alkyl, 
cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, 
sulfo-oxo, or thiol as described herein. 
The term “alkenyl” as used herein is a hydrocarbon group 
of from 2 to 24 carbon atoms With a structural formula con 
taining at least one carbon-carbon double bond. Asymmetric 
structures such as (AlA2)C:C(A3A4) are intended to 
include both the E and Z isomers. This can be presumed in 
structural formulae herein Wherein an asymmetric alkene is 
present, or it can be explicitly indicated by the bond symbol 
C:C. The alkenyl group can be substituted With one or more 
groups including, but not limited to, optionally substituted 
alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, 
cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic 
acid, ester, ether, halide, hydroxy, ketone, aZide, nitro, silyl, 
sulfo-oxo, or thiol, as described herein. 
The term “cycloalkenyl” as used herein is a non-aromatic 
carbon-based ring composed of at least three carbon atoms 
and containing at least one carbon-carbon double bound, i.e., 
C:C. Examples of cycloalkenyl groups include, but are not 
limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, 
cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbome 
nyl, and the like. The term “heterocycloalkenyl” is a type of 
cycloalkenyl group as de?ned above, and is included Within 
the meaning of the term “cycloalkenyl,” Where at least one of 
the carbon atoms of the ring is replaced With a heteroatom 
such as, but not limited to, nitrogen, oxygen, sulfur, or phos 
phorus. The cycloalkenyl group and heterocycloalkenyl 
group can be substituted or unsubstituted. The cycloalkenyl 
group and heterocycloalkenyl group can be substituted With 
one or more groups including, but not limited to, optionally 
substituted alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, 
alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, car 
boxylic acid, ester, ether, halide, hydroxy, ketone, aZide, 
nitro, silyl, sulfo-oxo, or thiol as described herein. 
The term “alkynyl” as used herein is a hydrocarbon group 
of 2 to 24 carbon atoms With a structural formula containing 
at least one carbon-carbon triple bond. The alkynyl group can 
be unsubstituted or substituted With one or more groups 
including, but not limited to, optionally substituted alkyl, 
cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalky 
nyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, 
ether, halide, hydroxy, ketone, aZide, nitro, silyl, sulfo-oxo, or 
thiol, as described herein. 
The term “cycloalkynyl” as used herein is a non-aromatic 
carbon-based ring composed of at least seven carbon atoms 
and containing at least one carbon-carbon triple bound. 
Examples of cycloalkynyl groups include, but are not limited 
to, cycloheptynyl, cyclooctynyl, cyclononynyl, and the like. 
The term “heterocycloalkynyl” is a type of cycloalkenyl 
group as de?ned above, and is included Within the meaning of 
the term “cycloalkynyl,” Where at least one of the carbon 
atoms of the ring is replaced With a heteroatom such as, but 
not limited to, nitrogen, oxygen, sulfur, or phosphorus. The 
cycloalkynyl group and heterocycloalkynyl group canbe sub 
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stituted or unsubstituted. The cycloalkynyl group and hetero 
cycloalkynyl group can be substituted With one or more 
groups including, but not limited to, optionally substituted 
alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, 
cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic 
acid, ester, ether, halide, hydroxy, ketone, aZide, nitro, silyl, 
sulfo-oxo, or thiol as described herein. 
The term “aryl” as used herein is a group that contains any 
carbon-based aromatic group including, but not limited to, 
benZene, naphthalene, phenyl, biphenyl, phenoxybenZene, 
and the like. The term “aryl” also includes “heteroaryl,” 
Which is de?ned as a group that contains an aromatic group 
that has at least one heteroatom incorporated Within the ring 
of the aromatic group. Examples of heteroatoms include, but 
are not limited to, nitrogen, oxygen, sulfur, and phosphorus. 
Likewise, the term “non-heteroaryl,” Which is also included 
in the term “aryl,” de?nes a group that contains an aromatic 
group that does not contain a heteroatom. The aryl group can 
be substituted or unsubstituted. The aryl group can be substi 
tuted With one or more groups including, but not limited to, 
optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl, 
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, alde 
hyde, amino, carboxylic acid, ester, ether, halide, hydroxy, 
ketone, aZide, nitro, silyl, sulfo-oxo, or thiol as described 
herein. The term “biaryl” is a speci?c type of aryl group and 
is included in the de?nition of “aryl.” Biaryl refers to tWo aryl 
groups that are bound together via a fused ring structure, as in 
naphthalene, or are attached via one or more carbon-carbon 
bonds, as in biphenyl. 
The term “alkylaryl” refers to alkyl-substituted aryl groups 
and “substituted alkylaryl” refers to alkylaryl groups further 
bearing one or more substituents as set forth above. 
The term “arylalkyl” refers to aryl-substituted alkyl groups 
and “substituted arylalkyl” refers to arylalkyl groups further 
bearing one or more substituents as set forth above. 
The term “arylalkenyl” refers to aryl-substituted alkenyl 
groups and “substituted arylalkenyl” refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term “arylalkynyl” refers to aryl-substituted alkynyl 
groups and “substituted arylalkynyl” refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term “aroyl” refers to aryl-substituted species such as 
benZoyl and “substituted aroyl” refers to aroyl moieties fur 
ther bearing one or more substituents as set forth above. 
The term “heteroaryl” refers to cyclic moieties containing 
one or more heteroatoms as part of the ring structure, and 
having in the range of 3 up to 12 carbon atoms and “substi 
tuted heteroaryl” refers to heterocyclic moieties further bear 
ing one or more substituents as set forth above. 
The term “acyl” refers to alkyl-carbonyl species. 
The term “halogen” refers to ?uoride, chloride, bromide or 
iodide atoms. 
As indicated above, an aspect of the present invention is the 
treatment of cancers including, for example, lung carcino 
mas, breast cancers, prostate cancers, cancers of the cervix 
and endometrium, neuroblastomas, lymphomas, gliomas, 
melanomas, squamous cell carcinomas, sarcomas, adenocar 
cinomas, astrocytomas, head-and-neck tumors, and G1 
tumors. 
One embodiment of the present invention is compounds of 
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and isomers, i.e. enantiomers, diastereomers, and geometri 
cal isomers thereof. 
In the above structures, Where the tWo dotted bonds in 
Structure 1 & Structure 2 can be either single bonds or double 
bonds, or a combination of both. When a double bond is 
present in Structure 2, the tWo possible E and Z forms are 
included. 
In the above formulas, X is chosen from O or N. Where R 
is hydrogen atom; methyl group; phenyl or substituted phenyl 
group. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R1 l are each 
independently selected from hydrogen; alkyl; substituted 
alkyl; cycloalkyl; substituted cycloalkyl, alkenyl; substituted 
alkenyl; alkynyl; substituted alkynyl; aryl; substituted aryl; 
alkylaryl; substituted alkylaryl; arylalkyl; substituted aryla 
lkyl; arylalkenyl; substituted arylalkenyl; arylalkynyl; substi 
tuted arylalkynyl; arylalkenyl; substituted arylalkenyl; aryla 
lkynyl; substituted arylalkynyl; heteroaryl; substituted 
heteroaryl; tri?uoromethyl; halogen; cyano; nitro; amidinea; 
amino; carboxyl; ester; alkylalkylamino; dialkylamino; 
hydroxyl; alkoxy or arylalkoxy (e.g. methoxy, ethoxy, ben 
Zyloxy, substituted benZyloxy). 
A pharmaceutical composition containing a compound of 
the invention is also contemplated, Which may include a 
conventional additive, such as a stabiliZer, buffer, salt, preser 
vative, ?ller, ?avor enhancer and the like, as knoWn to those 
skilled in the art. Representative buffers include phosphates, 
carbonates, citrates and the like. Exemplary preservatives 
include EDTA, EGTA, BHA, BHT and the like. A composi 
tion of the invention may be administered orally, i.e., in solid 
or liquid form (tablet, gel cap, time release capsule, poWder, 
solution, or suspension in aqueous or non aqueous liquid; 
intravenously as an infusion or injection, i.e., as a solution, 
suspension or emulsion in a pharmaceutically acceptable car 
ner. 
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7. RICN RIIH RZIH 
s. RIH RIIH RZIH 
9. RINOZ RIIH RZIH 
lO.R:Cl RIIH RZIH 
ll.R:COOCH3 RIIH RZIH 
12.R:H RIIBI RZIH 
13.R:F RIIH RZIH 
14.R:H RIIH RZICI 
15.R:OCH3 RIIH RZIBI 
16.R:H RIIH RZICH3 
17.R:H RIIH RZIBI 
18.R:H RIIH RZIOCH3 
19.R:CH3 RIIH RZIH 
Another embodiment of the present invention is the use of 
compounds disclosed herein in connection With at least one 
knoWn anti-cancer treatment. 
Thus, embodiments of the present invention relates to a 
method of treating cancer in a subject in need thereof, by 
administering to a subject in need thereof a ?rst amount of a 
compound of the present invention or a pharmaceutically 
acceptable salt or hydrate thereof, in a ?rst treatment proce 
dure, and a second amount of an anti-cancer agent in a second 
treatment procedure, Wherein the ?rst and second amounts 
together comprise a therapeutically effective amount. 
As discussed herein, treatment of cancer, as used herein, 
refers to partially or totally inhibiting, delaying or preventing 
the progression of cancer including cancer metastasis; inhib 












ing cancer metastasis; or preventing the onset or development 
of cancer (chemoprevention) in a mammal, for example a 
human. 
As discussed above, the methods of the present invention 
are useful in the treatment in a Wide variety of cancers, includ 
ing but not limited to solid tumors, hematological malignan 
cies, carcinomas, neuroblastoma, or melanoma. 
The invention further relates to pharmaceutical combina 
tions useful for the treatment of cancer. The pharmaceutical 
combination comprises a ?rst amount of a compound of the 
present invention, e.g., compound 1, and a second amount of 
an anti-cancer agent. The ?rst and second amount together 
comprise a therapeutically effective amount. 
The invention further relates to the use of a ?rst amount of 
a compound of the present invention and a second amount of 
an anti-cancer agent for the manufacture of a medicament for 
treating cancer. 
In particular embodiments of this invention, the combina 
tion of the compound of the present invention and anti-cancer 
agent is additive, i.e. the combination treatment regimen pro 
duces a result that is the additive effect of each constituent 
When it is administered alone. In accordance With this 
embodiment, the amount of a compound of the present inven 
tion and the amount of the anti-cancer together constitute an 
effective amount to treat cancer. 
In another particular embodiment of this invention, the 
combination of a compound of the present invention and 
anti-cancer agent is considered therapeutically synergistic 
When the combination treatment regimen produces a signi? 
cantly better anticancer result (e.g., cell groWth arrest, apop 
tosis, induction of differentiation, cell death) than the additive 
effects of each constituent When it is administered alone at a 
therapeutic dose. Standard statistical analysis can be 
employed to determine When the results are signi?cantly 
better. For example, a Mann-Whitney Test or some other 
generally accepted statistical analysis can be employed. 
The treatment procedures can take place sequentially in 
any order, simultaneously or a combination thereof. For 
example, the ?rst treatment procedure, administration of a 
compound of the present invention, can take place prior to the 
second treatment procedure, i.e. the anti-cancer agent, after 
the second treatment With the anticancer agent, at the same 
time as the second treatment With the anticancer agent, or a 
combination thereof. For example, a total treatment period 
can be decided for a compound of the present invention 
inhibitor. The anti-cancer agent can be administered prior to 
onset of treatment With the compound of the present invention 
or folloWing treatment With the compound of the present 
invention. In addition, treatment With the anti-cancer agent 
can be administered during the period of compound of the 
present invention administration but does not need to occur 
over the entire compound of the present invention treatment 
period. Similarly, treatment With the compound of the present 
invention can be administered during the period of anti-can 
cer agent administration but does not need to occur over the 
entire anti-cancer agent treatment period. In another embodi 
ment, the treatment regimen includes pre-treatment With one 
agent, either the compound of the present invention or the 
anti-cancer agent, folloWed by the addition of the second 
agent for the duration of the treatment period. 
In one particular embodiment of the present invention, the 
compound of the present invention can be administered in 
combination With any one or more of an additional compound 
of the present invention, an alkylating agent, an antibiotic 
agent, an antimetabolic agent, a hormonal agent, a plant 
derived agent, an anti-angiogenic agent, a differentiation 
inducing agent, a cell groWth arrest inducing agent, an apop 
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tosis inducing agent, a cytotoxic agent, a biologic agent, a 
gene therapy agent, or any combination thereof. 
The invention also includes methods of preventing the 
occurrence or progression of a cancer or a precancerous con 
dition in a mammal comprising administering to the mammal 
an effective amount of a composition comprising a compound 
of the present invention and a pharmaceutically acceptable 
carrier. 
The present invention also includes methods of treating or 
preventing cancer in a mammalian subject, comprising 
administering an effective amount to the mammalian subject 
a pharmaceutical preparation comprising a chemopreventive 
or chemotherapeutic compound of the present invention. 
Cancer, as used herein includes, but is not limited to, malig 
nant tumors, adenocarcinomas, carcinomas, sarcomas, 
malignant neoplasms, and leukemias. In particular epithelial 
cell derived cancers are intended to be encompassed by this 
invention. Examples of epithelial cell derived cancers that 
may be treated by the methods described herein include, but 
are not limited to, breast cancer, colon cancer, ovarian cancer, 
lung cancer or prostate cancer. Such cancers may be caused 
by, chromosomal abnormalities, degenerative groWth and 
developmental disorders, mitogenic agents, ultraviolet radi 
ating (UV), viral infections, oncogenes, mutations in genes, 
in-appropriate expression of a gene and presentation on a cell, 
or carcinogenic agent. 
Administration of the compositions of the present inven 
tion may be for either a prophylactic or therapeutic use. When 
provided prophylactically, a compound of the present inven 
tion is provided in advance of any symptoms due to the cancer 
af?icting the individual. Additionally, a compound of the 
present invention may be administered during or after cancer 
treatment to help prevent the reoccurrence of cancer. The 
prophylactic administration of the composition is intended as 
a chemopreventive therapy and serves to either prevent ini 
tiation of malignant cells or arrest or reverse the progression 
of transformed premalignant cells to malignant disease. 
When provided therapeutically the composition is pro 
vided at or after the onset of the disease. The therapeutic 
administration of the composition of this invention serves to 
attenuate or alleviate the cancer or facilitate regression of the 
cancer a?llicting the individual. The term individual is 
intended to include any animal, preferably a mammal, and 
most preferably a human. Veterinary uses are intended to be 
encompassed by this de?nition. 
In one embodiment of this invention, individuals at high 
risk for a particular cancer, or at high risk of reoccurrence of 
a cancer or Who have knoWn risk factors are prophylactically 
treated With the methods and compositions described herein. 
By Way of example, such individuals may include those With 
a familial history for either early or late onset of cancer, and 
individuals Who are being or have been treated for a cancer or 
cancer-related illness. 
General ranges of suitable effective prophylactic dosages 
that may be used are about 0.1 mg/kg of body Weight per day 
to about 500 mg/kg/day, a further range is about 0.5 mg/kg/ 
day to about 250 mg/kg/day, and as a further range, about 1 
mg/kg/day to about 100 mg/kg/day. 
The daily dose of the compound may be administered in a 
single dose or in portions at various hours of the day. Initially, 
a higher dosage may be required and may be reduced over 
time When the optimal initial response is obtained. By Way of 
example, treatment may be continuous for days, Weeks, or 
years, or may be at intervals With intervening rest periods. The 
dosage may be modi?ed in accordance With other treatments 
the individual may be receiving. One of skill in the art Will 












achieve the maximum effect for a given individual. It is fur 
ther understood by one skilled in the art that the dosage 
administered to a individual being treated may vary depend 
ing on the individuals age, severity or stage of the disease and 
response to the course of treatment. One skilled in the art Will 
knoW the clinical parameters to evaluate to determine proper 
dosage for the individual being treated by the methods 
described herein. 
Additional pharmaceutical methods may be employed to 
control the duration of action. Controlled release preparations 
may be achieved through the use of polymer to complex or 
absorb the proteins or their derivatives. The controlled deliv 
ery may be exercised by selecting appropriate macromol 
ecules (for example polyester, polyamino acids, polyvinyl, 
pyrrolidone, ethylenevinylacetate, methylcellulose, car 
boxymethylcellulose, or protamine sulfate) and the concen 
tration of macromolecules as Well as the methods of incorpo 
ration in order to control release. Alternatively, instead of 
incorporating these agents into polymeric particles, it is pos 
sible to entrap these materials in microcapsules prepared, for 
example, by coacervation techniques or by interfacial poly 
meriZation. 
When oral preparations are desired, the component may be 
combined With typical carriers/excipients, such as lactose, 
sucrose, starch, talc magnesium stearate, crystalline cellu 
lose, methyl cellulose, carboxymethyl cellulose, glycerin, 
sodium alginate or gum arabic among others. The only limi 
tation With resect to the carrier is that it does not deleteriously 
react With the active compound or is not deleterious to the 
recipient thereof. 
The pharmaceutical preparations can be steriliZed and if 
desired mixed With auxiliary agents, e.g., lubricants, preser 
vatives, stabiliZers, Wetting agents, emulsi?ers, salts for in?u 
encing osmotic pressure, buffers, colorings, ?avorings and/or 
aromatic substances and the like Which do not deleteriously 
react With the active compounds. 
As stated above, the administration of the compositions or 
of each individual component of the present invention may be 
for either a prophylactic or therapeutic purpose. The methods 
and compositions used herein may be used alone in prophy 
lactic or therapeutic uses or in conjunction With additional 
therapies knoWn to those skilled in the art in the prevention or 
treatment of cancer. Alternatively the methods and composi 
tions described herein may be used as adjunct therapy. 
It Will be appreciated that the actual preferred amounts of 
active compounds used in a given therapy Will vary according 
to the speci?c compound being utiliZed, the particular com 
positions formulated, the mode of application, the particular 
site of administration, etc. Optimal administration rates for a 
given protocol of administration can be readily ascertained by 
those skilled in the art using conventional dosage determina 
tion tests. 
The present invention also comprises methods of treating 
cancer comprising administering an anti-cancer agent, anti 
cancer chemotherapy and/ or anti-cancer radiation treatment; 
and administering a treatment enhancing amount of a com 
pound of the present invention. 
Yet another method of the present invention is a method for 
treating a malignancy in a mammal, comprising administer 
ing a pharmaceutical compound or composition of the present 
invention With a therapy selected from the group consisting of 
radioimmunoconjugate administration, other forms of 
radiopharmaceutical therapy, chemotherapy, external beam 
therapy, surgery, and other anti-malignancy treatment. 
Finally, another method of the present invention is a 
method of treating cancer comprising (a) administering to a 
patient in need of such treatment, a pharmaceutically-effec 
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tive amount of a composition of the present invention and (b) 
administering a therapy selected from radiation therapy and 
chemotherapy. 
EXAMPLES 
The following examples are put forth so as to provide those 
of ordinary skill in the art With a complete disclosure and 
description of hoW the compounds, compositions, articles, 
devices and/ or methods claimed herein are made and evalu 
ated, and are intended to be purely exemplary of the invention 
and are not intended to limit the scope of What the inventors 
regard as their invention. Efforts have been made to ensure 
accuracy With respect to numbers (e.g., amounts, tempera 
ture, etc.), but some errors and deviations should be 
accounted for. Unless indicated otherWise, parts are parts by 
Weight, temperature is in o C. or is at ambient temperature, 
and pressure is at or near atmospheric. 
Table 1: Table 1 shoWs the ef?ciency of various compounds 
synthesiZed in the present investigation as radiation sensitiZ 
ers. The values Were given as fraction of the cells survived 
When compared to DMSO control. Compounds 3, 4, and 15 
Were tested at 10 uM concentration. All other drugs Were 





DMSO + 6 Gy 0.34 
3 0.94 
3 + 6 Gy 0.43 
4 0.93 
4 + 6 Gy 0-14 
5 0.96 
5 + 4 Gy 0.45 
6 0.87 
6 + 6 Gy 0.51 
11 0.84 
11 + 6 Gy 0.29 
12 0.99 
12 + 6 Gy 0.40 
13 1.07 
13 + 6 Gy 0.33 
14 0.8 
14 + 6 Gy 0.38 
15 0.73 
15 + 6 Gy 0.32 
16 0.94 
16 + 6 Gy 0.38 
17 0.91 
17 + 6 Gy 0.33 
18 0.99 
18 + 6 Gy 0.47 
19 0.96 














4-((3 -((2,4,6-trioxotetrahydropyrimidin-5 (6H) 
ylidene)methyl)- 1 H -indol-1 -yl)meth-yl)b enZonitrile 
(1) 
A mixture of barbituric acid (1.28 g; 0.01 mol) and 4-((3 
formyl-1H-indol-1-yl)methyl)benZonitrile (2.60 g; 0.01 mol) 
in methanol (50 ml) Were stirred at room temperature. After 
10 min the reaction mixture became a solid suspension and 
the color of reaction mixture changed to yelloW color solid 
suspension. The suspension continued to stir at room tem 
perature for 5 hrs. Solid product Was separated by ?ltration 
and Washed several times With cold methanol (3x5 ml). The 
isolated yelloW solid recrystallized from methanol gave (1) as 
a yelloW crystalline product; m.p. >300o C.; 1H NMR 
(DMSO-d6): 6 5.81 (s, 2H), 7.33-7.36 (m, 2H), 7.43-7.45 (d, 
2H), 7.61-7.64 (m, 1H), 7.82-7.84 (d, 2H), 7.90-7.93 (m, 1H), 
8.68 (s, 1H), 9.63 (s, 1H), 11.07 (bs, 1H), 11.15 (bs, 1H); 13C 








A mixture of barbituric acid (1.28 g; 0.01 mol) and methyl 
4-((3-formyl-1H-indol-1-yl)methyl)benZoate (2.93 g; 0.01 
mol) in methanol (50 ml) Were stirred at room temperature. 
After 10 min the reaction mixture became a solid suspension 
and the color of reaction mixture changed to yelloW color 
solid suspension. The suspension continued to stir at room 
temperature for 5 hrs. Solid product Was separated by ?ltra 
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tion and Washed several times With cold methanol (3><5 ml). 
The isolated yelloW solid recrystallized from methanol gave 
(2) as a yelloW crystalline product; m.p. >300° C.; 1H NMR 
(DMSO-d6): 6 3.82 (s, 3H), 5.79 (s, 2H), 7.33-7.36 (m, 2H), 
7.40-7.42 (d, 2H), 7.61-7.63 (m, 1H), 7.91-7.93 (m, 1H), 
7.94-7.95 (d, 2H), 8.68 (s, 1H), 9.62 (s, 1H), 11.06 (bs, 1H), 
11.14 (bs, 1H); 13C NMR (DMSO-d6): 6 49.9, 52.1, 109.2, 




(Z) -4-((3 -((2,5 -dioxoimidaZolidin-4-ylidene)me 
thyl)-1H-indol-1 -yl)methyl)benZo nitrile (7) 
A mixture of hydantoin (1.00 g; 0.01 mol), 4-((3-formyl 
1H-indol-1-yl)methyl)benZonitrile (2.60 g; 0.01 mol) and 
ammonium acetate (0.77 g; 0.01 mol) in acetic acid (2.70 g; 
0.045 mol) Were re?uxed for 10 hrs. The reaction mixture Was 
cooled and Water (20 ml) Was added. Filtered the product and 
Washed With cold Water (2><5 ml). The crude product Was 
recrystallized from a mixture of methanol and ethyl acetate 
(1 :1 v/v) gave (3) as a yelloW crystalline product; m.p. >300° 
C.; 1H NMR (DMSO-d6): 6 5.56 (s, 2H), 6.73 (s, 1H), 7.13 
7.23 (m, 2H), 7.44-7.46 (d, 2H), 7.51-7.53 (d, 1H), 7.56 (m, 
3H), 8.30 (s, 1H), 10.15 (bs, 1H), 11.07 (bs, 1H); 13C NMR 




Plating E?iciency (PE) 
Human colon carcinoma cells (HT-29) Were groWn in 
DMEM/F-12 medium containing 10% fetal bovine serum 
(FBS). The cells Were inoculated into T25 ?asks (200-600 
cells per ?ask). All compounds/ drugs Were dissolved in 
DMSO. Cells Were treated either With carrier (DMSO) or 
drugs at 10-150 pM concentration. The ?asks Were incubated 
at 37° C. for 30 mins. After 30 mins incubation, the cells Were 
radiated using Cs source. The ?asks Were then incubated at 
37° C. for 90 mins. The medium Was removed and Washed 
With PBS. Fresh medium Was added to the ?asks and incu 
bated at 37° C. for several days (2-3 Weeks) to form colonies. 
The cells Were ?xed With methanol-acetic acid (3 :1 ratio) and 
stained With 1% crystal violet dye in methanol for 30 min. The 
excess dye Was Washed aWay With de-ioniZed Water, and the 
colonies Were counted. The plating e?iciency Was determined 












?asks With those obtained from control ?asks. Bar graphs 
Were created using the above data (FIG. 4). 
HSP70 Expression Experiment 
HT-29 cells Were plated and Were alloWed to groW to 75% 
con?uency. The cells Were treated either With DMSO or drugs 
for 2 hrs. Cells Were Washed With phosphate buffered saline 
(PBS, pH 7.2), fresh medium Was added, and incubated at 37° 
C. for 5 hrs. Then the cells Were Washed 3 times With cold 
PBS. Then, 150 pl of protein lysis buffer (50 mM Tris HCl, pH 
7.5, 150 mM NaCl, 1% NP-40, 10 mM EDTA, 0.1% SDS, 
0.5% deoxycholic acid and 10 pl/ml of protein inhibitor cock 
tail (Sigma, cat #E8230) Was added and the cells Were 
scraped. The lysate Was transferred to a fresh Eppendorf tube 
(1.5 ml) and sonicated for 5 seconds. The lysate Was centri 
fuged at 13000 rpm at 4° C. for 20 min. The supernatant Was 
transferred to fresh tubes and protein Was measured from each 
sample using a Biorad colorimetric assay. 20-40 pg of protein 
Was taken in a fresh tube and Was added equal volume of 5x 
Lemmeli buffer and the samples Were heated at 95° C. for 5 
min. The samples Were cooled and centrifuged brie?y. The 
samples Were loaded on polyacrylamide gels (10-12%) and 
resolved by gel electrophoresis. Then the proteins Were trans 
ferred onto a nitrocellulose membrane and the membrane Was 
blocked With 5% loW fat milk in TBS-T buffer (contains 0.2% 
Tween-20). HSP70 antibodies Were diluted 2000 fold in 5% 
milk in TBS-T and added to the membrane and shaken for 3-4 
hrs. Membranes Were Washed 3 times With 1-5% milk in 
TBS-T. HRP conjugated secondary antibodies Were diluted 
2000 fold in l-5% milk in TBS-T and incubated the mem 
brane for 45 min With shaking. The membrane Was Washed 3 
times With TBS-T for 10 min. each time. 10 ml of ECL 
reagent (Amersham) Was added to the membrane for 1 min. 
The membrane Was exposed to autoradiography ?lm and 
developed (FIG. 3) 
Gel Mobility Shift Assay 
HT-29 cells Were incubated at 37° C. for 2 hrs. in the 
presence of various concentrations of drugs. After the treat 
ment, cells Were Washed With PBS and fresh medium Was 
added. The ?asks Were incubated another 5 hrs at 37° C. Gel 
mobility shift assay Was done as described in Kim et al. 
(2006). Brie?y, the nuclear protein Was extracted With buffer 
containing 10 mM HEPES, 422 mM NaCl, 0.1 mM EGTA, 
5.3% glycerol, and protease inhibitor cocktail. Binding reac 
tions Were performed by adding 10-20 pg of cell extract to 0.2 
ng of 32P-labeled, double-stranded oligonucleotide contain 
ing rat Hsp70 heat shock element (Liu et al., 1993) in binding 
buffer [20 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT, 10% 
glycerol, 0.05% NP-40, 5 mM MgCl2, 0.05 pg of poly dl-dC] 
and incubating at 20° C. for 15 min. Competition binding 
reactions Were performed by addition of a 100-fold excess of 
unlabeled HSE to the binding reaction. 
Tubule Formation Assay 
Human umbilical vascular endothelial cells (HUVECs) 
(50,000 cells/Well) Were plated on Matrigel. After 30 min, the 
cells Were treated either With DMSO or 25 pM Compound 1. 
Tubule formation Was assessed by observing plates under 
microscope. FIG. 6 is represents 24 hr time point for DMSO 
and Compound 1. 
As indicated above, throughout this application, various 
references are mentioned. All references, speci?cally those 
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listed below, are incorporated herein by reference in their 
entirety and should be considered to be part of this applica 
tion. 
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The invention thus being described, it would be obvious 
that various changes in the details, steps and materials that 
have been described herein may be made by those skilled in 
the art within the principles and scope of the invention herein 
illustrated and de?ned in the appended claims. Therefore, 
while the present invention has been shown and described 
herein in what is believed to be the most practical and pre 
ferred embodiment, it is recogniZed that departures can be 












therefore not to be limited to the details disclosed herein but 
is to be accorded the full scope of the claims so as to embrace 
any and all equivalent apparatus and methods. 
We claim: 





(a) R2 is H and R7 is CN; or 
(b) R2 is H and R7 is COOCH3; or 
(c) R2 is H and R7 is H; or 
(d) R2 is H and R7 is N02; or 
(e) R2 is Cl and R7 is H; or 
(f) R2 is OCH3 and R7 is H; and pharmaceutical composi 
tions thereof. 
2. A compound of the following formula: 
NH 
0, wherein m2 
(a) R2 is H, R5 is H, and R7 is CN; or 
(b) R2 is H, R5 is H, and R7 is CN; or 
(c) R2 is H, R5 is H, and R7 is N02; or 
(d) R2 is H, R5 is H, and R7 is C1; or 
(e) R2 is H, R5 is H, and R7 is COOCH3; or 
(f) R2 is H, R5 is Br, and R7 is CN; or 
(g) R2 is H, R5 is H, and R7 is F; or 
(h) R2 is Cl, R5 is H, and R7 is CN; or 
(i) R2 is Br, R5 is H, and R7 is OCH3; or 
(i) R2 is CH3, R5 is H, and R7 is H; or 
(k) R2 is Br, R5 is H, and R7 is H; or 
(1) R2 is OCH3, R5 is H, and R7 is H; or 
(m) R2 is H, R5 is H, and R7 is CH3; and pharmaceutical 
compositions thereof. 
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3. A compound of claim 1, of the following formula: 
CN. 
4. A compound of claim 1, of the following formula: 
COOCH3. 
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X is O or N; R is H, methyl, phenyl or substituted phenyl; 
Rl-Rll are each independently selected from H, alkyl, sub 
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substi 
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi 
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky 
nyl, substituted arylalkynyl, arylalkenyl, substituted 
arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroaryl, 
substituted heteroaryl, tri?uoromethyl, halogen, cyano, nitro, 
amidinea, amino, carboxyl, ester, alkylalkylamino, dialky 
lamino, hydroxyl, alkoxy or arylalkoxy; and pharmaceutical 
compositions thereof. 















X is O or N; R is H, methyl, phenyl or substituted phenyl; 
Rl-Rll are each independently selected from H, alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, alk 
enyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substituted 
arylalkenyl, arylalkynyl, substituted arylalkynyl, aryla 
lkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heteroaryl, substituted heteroaryl, tri?uo 
romethyl, halogen, cyano, nitro, amidinea, amino, car 
boxyl, ester, alkylalkylamino, dialkylamino, hydroxyl, 
alkoxy or arylalkoxy; and pharmaceutical compositions 
thereof. 
9. A pharmaceutical composition comprising a compound 
of formula 11, and a pharmaceutically acceptable carrier. 
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10. A pharmaceutical composition comprising a com 
pound of formula 12, and a pharmaceutically acceptable car 
rier. 
11. A pharmaceutical composition comprising a com 
pound of formula 17, and a pharmaceutically acceptable car 
rier. 
12. A pharmaceutical composition comprising a com 
pound of formula 18, and a pharmaceutically acceptable car 
rier. 
24 
13. A pharmaceutical composition comprising a com 
pound of formula 11, and a pharmaceutically acceptable car 
rier. 
14. A pharmaceutical composition comprising a com 
pound of formula 11, and a pharmaceutically acceptable car 
rier. 
